Merck KGaA (ETR:MRK) has had a rough three months with its share price down 16%. But if you pay close attention, ...

Merck KGaA (OTC:MKGAF) is seeking worldwide regulatory approval for its CSF-1R inhibitor pimicotinib following robust Phase III results in tenosynovial giant cell tumour (TGCT). The MANEUVER trial ...

Business Wire India • Link to Live Stream of Inaugural Session of Merck Foundation First Ladies Initiative – MFFLI Summit 2025: Merck Foundation, the philanthropic arm of Merck KGaA Germany, ...

The Merck Foundation hosted its 7th Merck Foundation First Ladies Initiative (MFFLI) Summit in Dubai, focusing on enhancing ...

Merck KGaA has shed more light on the failure of its lupus drug in one cohort of patients, while pointing to secondary endpoint readouts as proof that the candidate still deserves a shot at ...

Merck KGaA has data from a pivotal study showing its once daily pill helped, leading to reduction in pain and improvement in physical movement. Regulatory submissions are now planned.

Merck KGaA (OTC:MKGAF) is seeking worldwide regulatory approval for its CSF-1R inhibitor pimicotinib following robust Phase III results in tenosynovial giant cell tumour (TGCT). The MANEUVER trial, ...

Merck KGaA has reached an agreement with SpringWorks on a $47-per-share takeover deal that values the US biotech at $3.9 billion. The acquisition – which was confirmed to be in the final stages ...

Merck KGaA is doubling down on AI through a new collaboration agreement with tech firm Iktos, using its generative modelling technology to speed up the discovery and design of promising new compounds.

Merck KGaA’s Rare Tumor Strategy Takes Shape With $3.9B SpringWorks Acquisition SpringWorks Therapeutics brings to Merck KGaA two FDA-approved drugs, both currently under regulatory review in ...

DARMSTADT, Germany, June 10, 2025--Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that the Center for Drug Evaluation (CDE) of the China National Medical ...

The studies are assessing the nanobody, which inhibits IL-17A and IL-17F, in patients with hidradenitis suppurativa. MoonLake licensed the candidate from Merck KGaA in 2021.